Evidence map›Paper›PMID 26632819›Full record

ArticlePloS one2015

Antimicrobial Non-Susceptibility of Escherichia coli from Outpatients and Patients Visiting Emergency Rooms in Taiwan.

Jann-Tay Wang, Shan-Chwen Chang, Feng-Yee Chang, Chang-Phone Fung, Yin-Ching Chuang, Yao-Shen Chen, Yih-Ru Shiau, Mei-Chen Tan, Hui-Ying Wang, Jui-Fen Lai and 2 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. The Resistance Patterns inTropical medicine and infectious disease · 2022
    Article
  4. Article
  5. Trends in Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Past and Present Perspectives on β-Lactamases.Antimicrobial agents and chemotherapy · 2018
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jann-Tay WangDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shan-Chwen ChangDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Feng-Yee ChangDivision of Infectious Diseases and Tropical Medicine, Tri-Service General Hospital, Taipei, Taiwan.
Chang-Phone FungDivision of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yin-Ching ChuangDepartment of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
Yao-Shen ChenDepartment of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Yih-Ru ShiauNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
Mei-Chen TanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
Hui-Ying WangNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
Jui-Fen LaiNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
I-Wen HuangNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
Tsai-Ling Yang LauderdaleNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Longitudinal nationwide surveillance data on antimicrobial non-susceptibility and prevalence of extended-spectrum β-lactamases (ESBLs) as well as AmpC β-lactamases producers among Escherichia coli from different sources in the community settings are limited. Such data may impact treatment practice. The present study investigated E. coli from outpatients and patients visiting emergency rooms collected by the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. A total of 3481 E. coli isolates were studied, including 2153 (61.9%) from urine and 1125 (32.3%) from blood samples. These isolates were collected biennially between 2002 and 2012 from a total of 28 hospitals located in different geographic regions of Taiwan. Minimum inhibitory concentrations (MIC) were determined using methods recommended by the Clinical Laboratory Standards Institute (CLSI). The prevalence and factors associated with the presence of ESBL and AmpC β-lactamase-producers were determined. Significant increases in non-susceptibility to most β-lactams and ciprofloxacin occurred during the study period. By 2012, non-susceptibility to cefotaxime and ciprofloxacin reached 21.1% and 26.9%, respectively. The prevalence of ESBL- and AmpC- producers also increased from 4.0% and 5.3%, respectively, in 2002-2004, to 10.7% for both in 2010-2012 (P < 0.001). The predominant ESBL and AmpC β-lactamase genes were CTX-M and CMY-types, respectively. Non-susceptibility of urine isolates to nitrofurantoin remained at around 8% and to fosfomycin was low (0.7%) but to cefazolin (based on the 2014 CLSI urine criteria) increased from 11.5% in 2002-2004 to 23.9% in 2010-2012 (P <0.001). Non-susceptibility of isolates from different specimen types was generally similar, but isolates from elderly patients were significantly more resistant to most antimicrobial agents and associated with the presence of ESBL- and AmpC- β-lactamases. An additional concern is that decreased ciprofloxacin susceptibility (MIC 0.12-1 mg/L) was as high as 25% in isolates from all age groups, including those from pediatric patients. Our data indicated that there is a need to re-evaluate appropriate treatment selection for community-acquired infections in Taiwan. Identification of community reservoirs of multidrug-resistant E. coli is also warranted.

Indexed as

Emergency Service, HospitalAdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsChildChild, PreschoolDrug Resistance, BacterialEscherichia coliFemaleHumansMaleMiddle AgedOutpatientsTaiwanAnti-Bacterial Agents

Identifiers

PMID26632819
PMCPMC4669119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.